Biopharma Daily Stock Updates - 03/27/21

$XBI $129.36 -3%

Covid Updates

$VIR -6% Ph 2 data combo w/ $GSK $LLY. source

$GRTS +1% 1st patient dosed in ph 1 study. source

$HGEN +60% Ph 3 data, Lenzilumab improves survival without ventilation in hospitalized covid-19 patients. source

$CYDY +4% Philippines approval of Leronlimab for covid-19. source

Pipeline Updates

$WVE -18% Ph 1b/2a results do not support further development. source

$MIRM +4% NDA acceptance & priority review for maralixibat, PDUFA date 9/29/21. source

$TGTX -5% Complete rolling BLA for ubli + umbra in CLL. source

$QURE +4% Update on findings from HCC case in hemo b program. source

$CERC -7% WW license agreement with Kyowa for CERC-002. source

$AVEO -6% FOTIVDA added to clinical practice guidelines. source

$AMPH +0% FDA approval for dextrose injections. source

$BLUE +3% FDA approval of ide-cel for multiple myeloma. source

Finance Updates

$AMTI -2% Offering. source

$HGEN +60% Offering. source